Tafamidis
Brand name: Vyndamax
Rank #37 of 500 drugs by total cost
$511.1M
Total Cost
20,589
Total Claims
$511.1M
Total Cost
507
Prescribers
$25K
Cost per Claim
1,522
Beneficiaries
23,154
30-Day Fills
$1.0M
Avg Cost/Provider
41
Avg Claims/Provider
About Tafamidis
Tafamidis (sold as Vyndamax) was prescribed 20,589 times by 507 Medicare Part D providers in 2023, costing the program $511.1M. At $25K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 34 | Valbenazine Tosylate (Ingrezza) | $553.8M | 73,914 |
| 35 | Fluticasone Propion/Salmeterol (Advair Diskus) | $523.2M | 1,289,942 |
| 36 | Varicella-Zoster Ge/As01b/Pf (Shingrix) | $514.4M | 2,419,884 |
| 37 | Tafamidis (Vyndamax) | $511.1M | 20,589 |
| 38 | Fluticasone/Vilanterol (Breo Ellipta) | $493.0M | 909,837 |
| 39 | Tiotropium Bromide (Spiriva Handihaler) | $478.1M | 673,800 |
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology